[go: up one dir, main page]

PE20081505A1 - Inhibidores de serina palmitoiltransferasa - Google Patents

Inhibidores de serina palmitoiltransferasa

Info

Publication number
PE20081505A1
PE20081505A1 PE2007001803A PE2007001803A PE20081505A1 PE 20081505 A1 PE20081505 A1 PE 20081505A1 PE 2007001803 A PE2007001803 A PE 2007001803A PE 2007001803 A PE2007001803 A PE 2007001803A PE 20081505 A1 PE20081505 A1 PE 20081505A1
Authority
PE
Peru
Prior art keywords
alkyl
oxo
halogen
chlorophenyl
dihydro
Prior art date
Application number
PE2007001803A
Other languages
English (en)
Inventor
Gary Louis Bolton
Richard Henry Hutchings
William Keun Chan Park
Huis Chad Alan Van
Jeffrey Thomas Kohrt
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20081505A1 publication Critical patent/PE20081505A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE INDOLINONA, BENCIMIDAZOLONA O BENZOXAZOLONA DE FORMULA (I), DONDE E1 ES N O CH; E2 ES NR, O O CRaRb; R ES H, ALQUILO C1-C3, CH2-COOH, CH2-COO-ALQUILO C1-C6; Ra Y Rb SON H O ALQUILO C1-C3; LA LINEA PUNTEADA INDICA UN DOBLE ENLACE OPCIONAL; r ES UN ENTERO DE 0 A 2; r' Y r'' SON UN ENTERO DE 1 A 3; X ES H, HALOGENO, HALOGENO, OXO; =NOR'; R' ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; m Y n SON UN ENTERO DE 0 A 2; A ES ALQUILO C1-C6, ALQUENILO C2-C6, UN CARBOCICLO, ENTRE OTROS; R1 ES H, HALOGENO, CN, C(O)R5, ENTRE OTROS; R2 ES H, HALOGENO, CF3, ALCOXI C1-C3, ALQUILO C1-C3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: METILAMIDA DEL ACIDO 1-{1-[2-(4-CLOROFENIL)-2-OXOETILPIPERIDIN-4-IL}-2-OXO-2,3-DIHIDRO-1H-BENZOIMIDAZOL-5-CARBOXILICO, METILAMIDA DEL ACIDO 1-{1-[2-(4-CLOROFENIL)-2-OXOETIL]PIPERIDIN-4-IL}-6-FLUORO-2-OXO-2,3-DIHIDRO-1H-BENZOIMIDAZOL-5-CARBOXILICO, ESTER METILICO DEL ACIDO 1-{1-[2-(4-CLOROFENIL)-2-OXOETIL]PIPERIDIN-4-IL}-6-FLUORO-2-OXO-2,3-DIHIDRO-1H-BENZOIMIDAZOL-5-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA SERINA PALMITOILTRANSFERASA Y SON UTILES EN EL TRATAMIENTO DE LA DIABETES TIPO 2, RESISTENCIA A LA INSULINA, SINDROME METABOLICO, ENTRE OTROS
PE2007001803A 2006-12-20 2007-12-14 Inhibidores de serina palmitoiltransferasa PE20081505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87598806P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
PE20081505A1 true PE20081505A1 (es) 2008-10-24

Family

ID=39361479

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001803A PE20081505A1 (es) 2006-12-20 2007-12-14 Inhibidores de serina palmitoiltransferasa

Country Status (10)

Country Link
US (1) US20080287479A1 (es)
EP (1) EP2121656A1 (es)
JP (1) JP2010513456A (es)
AR (1) AR064423A1 (es)
CA (1) CA2671138A1 (es)
CL (1) CL2007003733A1 (es)
PE (1) PE20081505A1 (es)
TW (1) TW200831487A (es)
UY (1) UY30807A1 (es)
WO (1) WO2008084300A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20090284A1 (it) * 2009-02-26 2010-08-27 Consiglio Nazionale Ricerche Uso di inibitori della serina palmitoiltrasferasi per la prevenzione e il rallentamento delle degenerazioni retiniche ereditarie e relative composizioni
EP2275421A1 (en) 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
WO2012047703A2 (en) * 2010-10-04 2012-04-12 Schering Corporation Cyclopropyl-spiro-piperidines useful as sodium channel blockers
FR2967673B1 (fr) 2010-11-24 2012-12-28 Minakem Synthese de n-heterocycles par alkylation reductrice de derives cyanes
CN102617548A (zh) * 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
HRP20161481T1 (hr) 2011-02-23 2016-12-30 Lupin Limited Derivati heteroarila kao modulatori nachr alfa7
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG11201405239WA (en) 2012-03-06 2014-09-26 Lupin Ltd Thiazole derivatives as alpha 7 nachr modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9273067B2 (en) * 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US10189785B2 (en) 2015-04-20 2019-01-29 Takeda Pharmaceuticals Company Limited Heterocyclic compound
WO2018074461A1 (ja) * 2016-10-18 2018-04-26 武田薬品工業株式会社 複素環化合物
CN110891949B (zh) * 2017-07-05 2023-05-23 先正达参股股份有限公司 具有含硫取代基的杀有害生物活性杂环衍生物
CN108689875A (zh) * 2018-07-18 2018-10-23 陕西恒润化学工业有限公司 一种环酰菌胺及其合成方法
MY204101A (en) * 2018-10-30 2024-08-07 Dow Global Technologies Llc Production of hydroxyethylpiperazine
KR20220006571A (ko) 2019-05-09 2022-01-17 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
IL301791A (en) * 2020-10-08 2023-05-01 Merck Sharp ַ& Dohme Llc Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
CA3195032A1 (en) * 2020-10-08 2022-04-14 Yeon-Hee Lim Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
DE102023128760A1 (de) * 2023-10-19 2025-04-24 Universitätsklinikum Jena, Körperschaft des öffentlichen Rechts Inhibitoren der Serin-Palmitoyltransferase zur Behandlung von Fettleibigkeit

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325499A (en) * 1964-11-02 1967-06-13 Mcneilab Inc 1-(1-hydrocarbyl-4-piperdyl)-2-indolinone
AU5002196A (en) * 1995-03-28 1996-10-16 Novo Nordisk A/S Immunosuppressive agents
WO1997040035A1 (en) * 1996-04-19 1997-10-30 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
KR100878774B1 (ko) * 2001-04-18 2009-01-14 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
EP1386920A4 (en) * 2001-04-20 2005-09-14 Banyu Pharma Co Ltd benzimidazolone derivatives
AU2005295080A1 (en) * 2004-10-12 2006-04-20 Transition Therapeutics Inc. Compounds and methods of treating insulin resistance and cardiomyopathy

Also Published As

Publication number Publication date
TW200831487A (en) 2008-08-01
EP2121656A1 (en) 2009-11-25
UY30807A1 (es) 2008-07-31
CL2007003733A1 (es) 2008-07-18
CA2671138A1 (en) 2008-07-17
WO2008084300A1 (en) 2008-07-17
US20080287479A1 (en) 2008-11-20
JP2010513456A (ja) 2010-04-30
AR064423A1 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
PE20081505A1 (es) Inhibidores de serina palmitoiltransferasa
PE20090159A1 (es) COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
PE20091841A1 (es) Inhibidores del virus de hepatitis c
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20081532A1 (es) Compuestos novedosos
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20080519A1 (es) Derivados de ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-1-il-piridin-3-ilamino)pirimidin-4-iloxi]-piperidina-1-carboxilico y sus composiciones farmaceuticas
PE20081659A1 (es) Agonistas de gpcr
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20080970A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20120812A1 (es) Compuestos vinil indazolilo
UY28493A1 (es) Metanosulfonato del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico y su utilización como medicamento.
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20120024A1 (es) DERIVADOS DE LA PIRIDINA SUSTITUIDO CON ANILLO HETEROCICLICO Y GRUPO y- GLUTAMINICO, Y AGENTES ANTIFUNGALES QUE LOS CONTIENEN

Legal Events

Date Code Title Description
FA Abandonment or withdrawal